Join
Live feed
·
NEWSReleasevia Quantisnow
Humanigen Inc. logo

Humanigen Tweets 'Lenzilumab Being Studied As A Potential First Treatment In Thirty Years With A Novel Mechanism Of Action For Chronic Myelomonocytic Leukemia (CMML), An Orphan Form Of Leukemia'

ByQuantisnow·Wall Street's wire, on your screen.
HGEN· Humanigen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track HGEN (Humanigen Inc.) and more on Quantisnow.